|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu
D, Gong S and Zhu Y: Identification of candidate diagnostic and
prognostic biomarkers for pancreatic carcinoma. EBioMedicine.
40:382–393. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen PA, Donini CF, Nguyen NT, Lincet H
and Vendrell JA: The dark side of ZNF217, a key regulator of
tumorigenesis with powerful biomarker value. Oncotarget.
6:41566–41581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang ZC, Zheng LQ, Pan LJ, Guo JX and
Yang GS: ZNF217 is overexpressed and enhances cell migration and
invasion in colorectal carcinoma. Asian Pac J Cancer Prev.
16:2459–2463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bellanger A, Donini CF, Vendrell JA,
Lavaud J, Machuca-Gayet I, Ruel M, Vollaire J, Grisard E, Győrffy
B, Bièche I, et al: The critical role of the ZNF217 oncogene in
promoting breast cancer metastasis to the bone. J Pathol.
242:73–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Si W, Zhao Y, Zhou J, Zhang Q and Zhang Y:
The coordination between ZNF217 and LSD1 contributes to
hepatocellular carcinoma progress and is negatively regulated by
miR-101. Exp Cell Res. 379:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Almuttaqi H and Udalova IA: Advances and
challenges in targeting IRF5, a key regulator of inflammation. FEBS
J. 286:1624–1637. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Massimino M, Vigneri P, Fallica M, Fidilio
A, Aloisi A, Frasca F and Manzella L: IRF5 promotes the
proliferation of human thyroid cancer cells. Mol Cancer. 11:212012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bai Q, Liu L, Xia Y, Wang J, Xi W, Qu Y,
Xiong Y, Long Q, Xu J, Guo J, et al: IRF5 is associated with
adverse postoperative prognosis of patients with non-metastatic
clear cell renal cell carcinoma. Oncotarget. 8:44186–44194. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dong SM, Lee HG, Cho SG, Kwon SH, Yoon H,
Kwon HJ, Lee JH, Kim H, Park PG, Kim H, et al: Hypermethylation of
the interferon regulatory factor 5 promoter in Epstein-Barr
virus-associated gastric carcinoma. J Microbiol. 53:70–76. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rawla P, Sunkara T and Gaduputi V:
Epidemiology of pancreatic cancer: Global trends, etiology and risk
factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang X, Zhang C, Qi S, Guo S, Chen Y, Du
E, Zhang H, Wang X, Liu R, Qiao B, et al: Elevated expression of
ZNF217 promotes prostate cancer growth by restraining
ferroportin-conducted iron egress. Oncotarget. 7:84893–84906. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Z, Du L, Dong Z, Yang Y, Zhang X, Wang
L, Li J, Zheng G, Qu A and Wang C: MiR-203 suppresses ZNF217
upregulation in colorectal cancer and its oncogenicity. PLoS One.
10:e01161702015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L, Hao R, Tian F, An N and Wang K:
Interferon regulatory factor 5 (IRF5) regulates the expression of
matrix metalloproteinase-3 (MMP-3) in human chondrocytes. Int
Immunopharmacol. 55:231–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pimenta EM and Barnes BJ: A conserved
region within interferon regulatory factor 5 controls breast cancer
cell migration through a cytoplasmic and transcription-independent
mechanism. Mol Cancer. 14:322015. View Article : Google Scholar : PubMed/NCBI
|
